Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Update on Burkitt Lymphoma.

Hematology/oncology clinics of North America - 1 Dec 2016

Dunleavy Kieron, Little Richard F, Wilson Wyndham H

Abstract excerpt

Because of its rarity and high curability, progress in advancing therapeutics in Burkitt lymphoma (BL) has been difficult. Over recent years, several new mutations that cooperate with MYC have been identified, and this has paved the way for testing novel agents in the disease. One of the challenges of most standard approaches typically used is severe treatment-related toxicity that often leads to discontinuation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Burkitt Lymphoma
Share to MYC gene
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-myc

Source

Identifiers

PMID: 27888884
DOI: 10.1016/j.hoc.2016.07.009

Genes

MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Update on Burkitt Lymphoma.PMID 27888884Read ↗

The treatment of Burkitt lymphoma in adults.Semantic proximity Read ↗

Burkitt lymphoma: bridging the gap between advances in molecular biology and therapySemantic proximity Read ↗

Burkitt's lymphoma: molecular pathogenesis and treatment.Semantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

Burkitt Lymphoma and MYCSemantic proximity Read ↗

Drug therapy for double-hit lymphomaSemantic proximity Read ↗

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.Semantic proximity Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.Semantic proximity Read ↗

Double-Hit Large B Cell Lymphoma.Semantic proximity Read ↗

Development of molecular intervention strategies for B-cell lymphoma.Semantic proximity Read ↗

Emerging Strategies in Treating Double Hit Lymphomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.